11.14.22
Results from a large-scale, placebo controlled clinical trial known as CAPP2 (Colorectal Adenoma/Carcinoma Prevention Programme 2) showed a 60% reduction in non-colorectal cancer among adults with Lynch Syndrome (hereditary nonpolyposis colon cancer) taking resistant starch (RS), a prebiotic dietary fiber.
This effect was particularly pronounced for upper gastrointestinal cancers including esophageal, gastric, biliary tract, pancreatic, and duodenum cancers. The benefit lasted for 10 years after consumption of the supplement.
The study was published in Cancer Prevention Research in July of 2022.1
The average duration of consumption was 29 months and the mean age of participants was 45
This effect was particularly pronounced for upper gastrointestinal cancers including esophageal, gastric, biliary tract, pancreatic, and duodenum cancers. The benefit lasted for 10 years after consumption of the supplement.
The study was published in Cancer Prevention Research in July of 2022.1
Study Design and Details
The clinical trial included 463 adults who received 30 grams/day of a supplement containing approximately 13 grams of RS2 and RS3 resistant starch and 455 participants who received a highly digestible corn starch placebo.The average duration of consumption was 29 months and the mean age of participants was 45
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
